MTOR and neoplasm: The PI3K/AKT/mTOR pathway, associated with MT‐mediated resistance, can be targeted with everolimus to reduce mesenchymal markers and delay tumor recurrence in HNSCC, NSCLC, and renal cell cancer [191].